Loading...
Market
What will be the market share of Ozempic compared to other weight loss medications in China by end of 2024?
3
Resolution / Starting Odds
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Market analysis reports from pharmaceutical industry analysts
Story
China Adopts Ozempic in Weight Loss Guidelines, British Heart Foundation Optimistic
Sep 3, 2024, 06:04 AM
New guidelines from a leading medical advisory body in China are incorporating 'miracle cure' medications such as Ozempic into weight loss treatments, potentially changing the lives of millions and boosting sales for drugmakers. Bryan Williams from the British Heart Foundation expressed optimism about Ozempic's potential to help with extreme weight loss and other conditions. Ozempic, originally developed to treat diabetes, has shown promise in aiding weight loss and reducing risks of cardiovascular issues. Recent studies indicate that semaglutide, the active ingredient in Ozempic, is effective in reducing the progression from prediabetes to type 2 diabetes. Despite the enthusiasm, experts urge caution, noting the need for long-term studies to fully understand the drug's effects. Additionally, new research has found no increased risk of mental health issues among users of semaglutide for weight loss.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%